2 citations
,
November 2024 in “JAAD Case Reports” Anti-PD-L1 immunotherapy can cause hair loss and unexpected hair color change, but treatment can restore hair growth and color.
August 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” In this retrospective study of patients with advanced Merkel cell carcinoma responding to immunotherapy, those treated for 18 months or longer showed better progression-free outcomes compared to shorter treatment durations, indicating potential benefits of extended therapy duration.
12 citations
,
March 2021 in “JAAD Case Reports” This study reported that immunotherapy in cancer patients can lead to skin-related immune adverse events, such as rashes, pruritus, and vitiligo, affecting a substantial proportion of patients.
April 2016 in “Journal of Investigative Dermatology” This study found that the peptide derivative beta-Ala-Pro-Dab-NHbenzyl may reduce wrinkles and sebum production in human skin by inhibiting dipeptidyl peptidase 4, suggesting potential for acne and skin inflammation treatment.
2 citations
,
May 2023 in “Journal of Immunotherapy” In this case study, a 65-year-old male with hepatocellular carcinoma treated with the PD-1 inhibitor Sintilimab developed alopecia universalis alongside significant tumor regression and complete remission, highlighting a rare immune-related adverse event with effective anti-tumor outcomes.